A significant rate of Tet methylcytosine dioxygenase 2 (TET2) genetic changes is observed in AML, which significantly correlate with a decrease in 5-hydroxymethylcytosine (5hmC) levels, and these mutations are recognized as potential diagnostic and prognostic biomarkers for hematological malignancies. This evidence concerns the gene TET2 and acute myeloid leukemia.